Unknown

Dataset Information

0

PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer's Disease.

ABSTRACT: Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine kinase and an attractive therapeutic target for Alzheimer's disease. Based on proteolysis-targeting chimera (PROTAC) technology, a small set of novel GSK-3β degraders was designed and synthesized by linking two different GSK-3β inhibitors, SB-216763 and tideglusib, to pomalidomide, as E3 recruiting element, through linkers of different lengths. Compound 1 emerged as the most effective PROTAC being nontoxic up to 20 μM to neuronal cells and already able to degrade GSK-3β starting from 0.5 μM in a dose-dependent manner. PROTAC 1 significantly reduced the neurotoxicity induced by Aβ25-35 peptide and CuSO4 in SH-SY5Y cells in a dose-dependent manner. Based on its encouraging features, PROTAC 1 may serve as a starting point to develop new GSK-3β degraders as potential therapeutic agents.

SUBMITTER: Guardigni M 

PROVIDER: S-EPMC10251479 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Glycogen synthase kinase 3β (GSK-3β) is a serine/threonine kinase and an attractive therapeutic target for Alzheimer's disease. Based on proteolysis-targeting chimera (PROTAC) technology, a small set of novel GSK-3β degraders was designed and synthesized by linking two different GSK-3β inhibitors, SB-216763 and tideglusib, to pomalidomide, as E3 recruiting element, through linkers of different lengths. Compound <b>1</b> emerged as the most effective PROTAC being nontoxic up to 20 μM to neuronal  ...[more]

Similar Datasets

Unknown Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
| S-EPMC7004542 | biostudies-literature
Unknown Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
| S-EPMC7367341 | biostudies-literature
Unknown Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer's disease.
| S-EPMC7049105 | biostudies-literature
Unknown Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?
| S-EPMC8016207 | biostudies-literature
Unknown Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.
| S-EPMC7349761 | biostudies-literature
Unknown Glycogen synthase kinase 3β in tumorigenesis and oncotherapy (Review).
| S-EPMC7610307 | biostudies-literature
Unknown Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
| S-EPMC4800499 | biostudies-other
Unknown Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.
| S-EPMC3759928 | biostudies-literature
Unknown Glycogen Synthase Kinase 3β: A True Foe in Pancreatic Cancer.
| S-EPMC9696080 | biostudies-literature
Unknown Glycogen synthase kinase 3β represses MYOGENIN function in alveolar rhabdomyosarcoma.
| S-EPMC3944270 | biostudies-literature